Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.08
CTIC's Cash to Debt is ranked higher than
65% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. CTIC: 4.08 )
CTIC' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 4.08

Equity to Asset 0.45
CTIC's Equity to Asset is ranked higher than
61% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CTIC: 0.45 )
CTIC' s 10-Year Equity to Asset Range
Min: -2.06   Max: 0.94
Current: 0.45

-2.06
0.94
F-Score: 3
Z-Score: -28.17
M-Score: -0.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -143.54
CTIC's Operating margin (%) is ranked higher than
70% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. CTIC: -143.54 )
CTIC' s 10-Year Operating margin (%) Range
Min: -123250   Max: -119.75
Current: -143.54

-123250
-119.75
Net-margin (%) -155.41
CTIC's Net-margin (%) is ranked higher than
68% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. CTIC: -155.41 )
CTIC' s 10-Year Net-margin (%) Range
Min: -169773.75   Max: -123.26
Current: -155.41

-169773.75
-123.26
ROE (%) -330.82
CTIC's ROE (%) is ranked higher than
51% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. CTIC: -330.82 )
CTIC' s 10-Year ROE (%) Range
Min: -520.3   Max: -42.02
Current: -330.82

-520.3
-42.02
ROA (%) -121.84
CTIC's ROA (%) is ranked higher than
54% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. CTIC: -121.84 )
CTIC' s 10-Year ROA (%) Range
Min: -261.37   Max: -20.35
Current: -121.84

-261.37
-20.35
ROC (Joel Greenblatt) (%) -1529.23
CTIC's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. CTIC: -1529.23 )
CTIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2180.72   Max: -48.38
Current: -1529.23

-2180.72
-48.38
EBITDA Growth (3Y)(%) -28.60
CTIC's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. CTIC: -28.60 )
CTIC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -71.5   Max: 50.1
Current: -28.6

-71.5
50.1
EPS Growth (3Y)(%) -100.00
CTIC's EPS Growth (3Y)(%) is ranked higher than
57% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CTIC: -100.00 )
CTIC' s 10-Year EPS Growth (3Y)(%) Range
Min: -100   Max: 64
Current: -100

-100
64
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CTIC Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

CTIC Guru Trades in Q2 2014

Jim Simons 692,650 sh (New)
» More
Q3 2014

CTIC Guru Trades in Q3 2014

Jim Simons 1,010,871 sh (+45.94%)
» More
Q4 2014

CTIC Guru Trades in Q4 2014

Jim Simons 587,916 sh (-41.84%)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.70
CTIC's P/B is ranked higher than
63% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. CTIC: 7.70 )
CTIC' s 10-Year P/B Range
Min: 5.71   Max: 122
Current: 7.7

5.71
122
P/S 4.70
CTIC's P/S is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. CTIC: 4.70 )
CTIC' s 10-Year P/S Range
Min: 0.06   Max: 40559.92
Current: 4.7

0.06
40559.92
EV-to-EBIT -3.12
CTIC's EV-to-EBIT is ranked higher than
56% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CTIC: -3.12 )
CTIC' s 10-Year EV-to-EBIT Range
Min: -178.3   Max: -0.1
Current: -3.12

-178.3
-0.1
Current Ratio 2.22
CTIC's Current Ratio is ranked higher than
62% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CTIC: 2.22 )
CTIC' s 10-Year Current Ratio Range
Min: 0.42   Max: 17.35
Current: 2.22

0.42
17.35
Quick Ratio 2.10
CTIC's Quick Ratio is ranked higher than
63% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CTIC: 2.10 )
CTIC' s 10-Year Quick Ratio Range
Min: 0.42   Max: 17.28
Current: 2.1

0.42
17.28
Days Inventory 1.00
CTIC's Days Inventory is ranked higher than
99% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CTIC: 1.00 )
CTIC' s 10-Year Days Inventory Range
Min: 16.31   Max: 8925.18
Current: 1

16.31
8925.18
Days Sales Outstanding 12.22
CTIC's Days Sales Outstanding is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. CTIC: 12.22 )
CTIC' s 10-Year Days Sales Outstanding Range
Min: 2.47   Max: 1460
Current: 12.22

2.47
1460

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.54
CTIC's Price/Tangible Book is ranked higher than
69% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. CTIC: 7.54 )
CTIC' s 10-Year Price/Tangible Book Range
Min: 4.19   Max: 1492
Current: 7.54

4.19
1492
Earnings Yield (Greenblatt) -31.20
CTIC's Earnings Yield (Greenblatt) is ranked lower than
55% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CTIC: -31.20 )
CTIC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -31.5   Max: 0
Current: -31.2

-31.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0QUJ.UK, CTIC.Italy, CEPR.Germany,
CTI Biopharma Corp was incorporated in Washington in 1991. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. In May 2012, it expanded its late-stage pipeline of product candidates with the acquisition of pacritinib, an oral inhibitor of both Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase, or FLT3, which demonstrated meaningful clinical benefits and good tolerability in myelofibrosis patients in Phase 2 clinical trials. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies.The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of its products are extensively regulated by governmental authorities in the U.S. and other countries.
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
comment on CTIC Dec 16 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 26 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 29 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 10 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 04 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 18 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 11 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 06 2010 

More From Our Partners
What Makes CTI BioPharma (CTIC) a Strong Sell? - Tale of the Tape Mar 26 2015 - ZACKS

More From Other Websites
What Makes CTI BioPharma (CTIC) a Strong Sell? - Tale of the Tape Mar 26 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Mar 23 2015
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene Mar 20 2015
CTI BIOPHARMA CORP Financials Mar 19 2015
Small Biotech Firm Quietly Makes +1,000% Price Move Mar 17 2015
3 Stocks Near 52-Week Lows to Buy Now - Analyst Blog Mar 16 2015
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With... Mar 16 2015
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With... Mar 16 2015
3 Biotech Stocks on Traders' Radars: Technical Charts Mar 13 2015
CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing Mar 13 2015
CTI BioPharma reports 4Q loss Mar 12 2015
CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results Mar 12 2015
CTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET today Mar 12 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Mar 12 2015
CTI BIOPHARMA CORP Files SEC form 10-K, Annual Report Mar 12 2015
CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results Mar 12 2015
Q4 2014 CTi Biopharma Corp Earnings Release - After Market Close Mar 12 2015
CTI BioPharma (CTIC) Shows Strength: Stock Moves Up 6.4% - Tale of the Tape Mar 10 2015
4 Big Stocks on Traders' Radars: Rite Aid, BlackBerry and More Mar 10 2015
Biotech Company Could Be on the Cusp of New Proenzyme Drug for the Treatment and Prevention of... Mar 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK